Short bowel syndrome (SBS) is a complex condition that occurs due to the resection or malformation of the small intestine, resulting in the inability to absorb enough nutrients and fluids from food. The symptoms of SBS include diarrhea, dehydration, malnutrition and weight loss. Current therapies aim to manage these symptoms and improve nutrition through dietary changes, intravenous supplementation, and medications. The global SBS therapeutics market consists of medications such as glucagon-like peptide-2 analogs and growth hormone that help increase intestinal absorption and reduce dependence on parenteral support. The market also includes dietary supplements that provide essential nutrients to SBS patients. Emerging pipeline therapies including teduglutide and allogeneic hematopoietic stem cell therapy offer promise to further improve outcomes in SBS.

The global Short Bowel Syndrome Market is estimated to be valued at US$ 7,310.1 Mn in 2023 and is expected to exhibit a CAGR of 5.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/short-bowel-syndrome-market-169

Market key trends:

One of the major trends in the SBS market is the rising clinical pipeline for novel therapeutics. Several pharmaceutical companies are conducting clinical trials evaluating new drug candidates that can help enhance intestinal function and absorption in SBS patients. For instance, Zealand Pharma is evaluating a GLP-2 analog called glepaglutide in late-stage trials. Glepaglutide is a long-acting GLP-2 therapy administered weekly as opposed to daily, promising better treatment adherence. Similarly, Takeda is developing an allogeneic hematopoietic stem cell therapy in Phase 3 studies that could enable patients to regain independent intestinal function. A thriving pipeline of novel drugs can potentially drive greater adoption and market growth over the coming years.

Porter’s Analysis

Threat of new entrants: The threat of new entrants is low in the short bowel syndrome market due to high capital requirements and presence of established market players.

Bargaining power of buyers: The bargaining power of buyers is moderate as the treatment options for short bowel syndrome are limited. However, availability of substitutes provide some bargaining power to buyers.

Bargaining power of suppliers: The bargaining power of suppliers is low due to presence of a large number of suppliers and low differentiation in products.

Threat of new substitutes: The threat of new substitutes is moderate due to continued research focusing on developing new treatment options.

Competitive rivalry: The competitive rivalry is high among key players to gain higher market share through product innovations and strategic collaborations.

Key Takeaways

The global short bowel syndrome market is expected to witness high growth over the forecast period. The global Short Bowel Syndrome Market is estimated to be valued at US$ 7,310.1 Mn in 2023 and is expected to exhibit a CAGR of 5.5% over the forecast period 2023 to 2030.

Regional analysis

North America is expected to continue its dominance during the forecast period. This is attributed to increasing incidences of short bowel syndrome, supportive reimbursement policies, and new product launches. Europe held the second largest share in 2020 led by Germany, UK and France while Asia Pacific is projected to grow at the fastest CAGR during the forecast period with China and India being the major contributors.

Key players

Key players operating in the short bowel syndrome market are United Therapeutics Corporation, GlaxoSmithKline plc., Novartis AG, AstraZeneca, Bayer AG, Merck KGaA, Pfizer Inc., Gilead Sciences, Inc., Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, Daiichi Sankyo Company, Limited, Sandoz AG, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd. and Mylan N.V. United Therapeutics Corporation dominates the market with its product Teduglutide